Irbesartan/Hydrochlorthiazid Medical Valley (Hydrochlorothiazide, Irbesartan)

• Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.
• Hypertension: lowers systolic and diastolic blood pressure and reduces the risk of cardiovascular complications.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume, together producing a synergistic antihypertensive effect.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury or worsening renal function
• Hyperkalemia, especially when combined with potassium‑sparing agents
• Angioedema or severe allergic reaction
• Significant drops in blood pressure (hypotension)
• Hepatic dysfunction or jaundice

Irbesartan/Hydrochlorothiazide should be used with careful clinical monitoring.

• Blood Pressure Monitoring: check regularly to avoid hypotension.
• Renal Function: assess serum creatinine and eGFR before and during therapy.
• Electrolyte Balance: monitor potassium and sodium levels, especially in patients on other diuretics.
• Elderly Patients: start at lower doses and watch for orthostatic symptoms.
• Pregnancy and Breastfeeding: avoid use unless benefits clearly outweigh risks.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment
• Lithium: increased lithium levels and toxicity risk
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia
• ACE inhibitors or other ARBs: additive effect on potassium and renal function
• NSAIDs: may reduce antihypertensive efficacy and affect renal function

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may enhance blood‑pressure lowering effect
• CYP3A4 inhibitors (e.g., ketoconazole): can increase irbesartan exposure
• Antidiabetic agents: diuretic‑induced changes in glucose control
• Loop diuretics: additive diuretic effect, monitor volume status
• Antacids containing aluminum or magnesium: may affect absorption of hydrochlorothiazide